Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Dalmane. Every FDA application for this active ingredient: 1 branded and 22 generic.
As of Nov 16, 2026, FDA lists 23 applications for Flurazepam Hydrochloride (sold as Dalmane), first approved Apr 7, 1970, with 0 new uses approved and 0 published complete response letters.
First approved: Apr 7, 1970
Applications: 23
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $128K
Shortage: Current
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Flurazepam HCl
Part D
$128K
+70%
79
FDA Drug Safety Communications
One communication since 2020 that name this drug; see all communications
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA